Evgeniy Shpeer

Evgeniy Shpeer

Auto-generated profile, based on publicly available information

Evgeniy Shpeer

GSK, Moscow, Russia

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
8 March 2022 in Human Vaccines & Immunotherapeutics
Verified
Journal Article
Open access
AMAlen Marijam
Alen Marijam
ESEkaterina Safonova
Ekaterina Safonova
MSMikhail Scherbakov
Mikhail Scherbakov
ESEvgeniy Shpeer
Evgeniy Shpeer
DODesirée Van Oorschot
Desirée Van Oorschot
NBNikolay Briko
Nikolay Briko
This economic evaluation assesses the cost-effectiveness and budget impact of introducing a two-dose varicella vaccine in the Russian national immunization program. A static Markov model followed a simulated 2019 Russian cohort over its lifetime and compared outcomes and costs of three varicella vaccination strategies: strategy I (doses given at 12 and 15 months of age), strategy II (doses given at 1 year and 6 years of age), and a no vaccination scenario. Inputs on age-dependent clinical pathways, associated costs, and related health outcomes were collected from national sources and published literature. Results are presented as incremental cost-effectiveness ratio (ICER) from the healthcare payer and societal perspective over the lifetime of the birth cohort and the budget impact over a 10 years’ time horizon. Vaccination strategies I and II resulted in an ICER of approximately 1.7 million rubles per quality-adjusted life years gained from the healthcare payer perspective and were cost-saving from the societal perspective. From the healthcare payer perspective, the costs per varicella case averted were 5,989 and 7,140 rubles per case for strategies I and II, respectively. However, from the societal perspective, vaccination is a dominant strategy and the budget impact analysis shows significant healthcare savings over 10 years, with strategy I realizing savings of ~2 billion rubles more than strategy II. From a public health impact perspective, varicella vaccination of children at 12 and 15 months of age through the Russian NIP is expected to be cost-effective with an affordable budget impact compared to no vaccination. A graphical version of the plain language summary can be found here: 10.6084/m9.figshare.19291463 Focus on the patient What is the context? What is new? What is the impact? Graphical Abstract